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The synthesis of four biotin derivatives carrying two DOTA moieties for each ligand (BisDOTA set) is
reported, for increasing radiation/dose ratio and improving efficiency in the pretargeted avidin-biotin
radioimmunotherapy. The biotin-containing scaffold of two BisDOTAwas similar to themono-DOTA
derivative previously described. Then the scaffold was elongated by trifunctionalized spacers of
different length and conjugated with one of the COOH groups of two DOTA. Two others were
prepared starting from a on-resin lysine residue. The lysine R-NH2 was bonded to biotin, and then
spacers were appended to the ε-NH2 and conjugated with two DOTA molecules. One compound
contained a p-aminobenzoic acid spacer, which ensured higher head-to-tail distance and increased
rigidity of the chain. These last two compounds had a very high ability to bond avidin and were labeled
with 90Y at high specific activity. All the compounds were resistant to the action of serum biotinidases.
Introduction
Tumor therapy is mostly implemented through the use of
substances targeted at destroying cancer cells. This can be
achieved with cytotoxic substances, which have to penetrate
into the tumor cells in order to exert their full effect or by
means of treatment of the tumor cells with radiation of
sufficient energy to kill the cells. In both cases the main
problem is to deliver the substance in a selective manner to
the target cells to avoid possible damage to the surrounding
healthy cells. The very high binding affinity of (þ)-biotin
toward the xenobiotic proteins avidin (Av) and streptavidin
(Sav)1 prompted researches in multidiscipcilinary fields to
address the use of labeled biotin derivatives, in combination
with Av or Sav and monoclonal antibodies (MoAbs), for
delivering diagnostic or therapeutic radionuclides to cancer
cells.2Actually, the so-called pretargetingprotocols arewidely
used in the clinical practice3-8 and, among them, the flexible
three-steps method appeared especially useful for therapy of
several type of tumors.7,9-13 In designing new biotin conju-
gates for pretargeted radiotherapy of cancer, onemust take in
account that amide bonds between the valeric acid side arm of
biotin and the spacer carrying the radiolabeled moiety could
be degraded by the action of the serum biotinidases.14 At the
same time, molecular changes of the biotin side arm, carrying
the radionuclide chelating unity, can affect the binding to Av
or Sav, diminishing the affinity and causing loss of the
radiating potency on cancer cells. The pivotal work of Wil-
bur’s group14,15 and of other researchers16 has highlighted
some structural characteristics of the biotin conjugates which
hamper the action of biotinidase and allow retention of high
affinity forAv and Sav pockets. Recently, J. Hainsworth et al.
demonstrated that DOTAa-(R)-biotinamidolysine (Chart 1)
is 93% streptavidin bound and that this molecule shows high
stability in serum.17On the other hand,Pazy et al. showed that
the Av pocket is much more sensible than Sav to structural
changes on the biotin side chain, which caused the disordered
conformation of a critical loop.18 On the basis of these
findings, these authors suggested an explanation of the funda-
mental role of streptavidin when administred in the three-step
procedure.13,14 Recently, we prepared a new biotin-mono-
DOTA conjugate, r-BHD (Chart 2),19 where the original
carboxy group of the biotin was bonded to diaminohexane,
then the amide CO reduced to CH2 group, and finally, theN-
hexylamine coupled to one of the four carboxymethyl chains
of DOTA chelator. Preclinical evaluations (radiolabeling
studies, binding toAv, and in vitro stability of the 90Y labeled
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ren-9-ylmethyloxycarbonyl; HABA, 40-hydroxyazobenzene-2-carboxylic
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complex) suggested that this bioconjugate is a good candidate
for future applications in pretargeting protocols.19 However,
in the three-step pretargeting technique, the radioactivity is
carried on the tumor by the radiolabeled biotin functionalized
with the suitable chelating agent. Since only a small percen-
tage really localizes on the tumoral lesion, it is important that
the DOTA-biotin conjugate is labeled at high specific activ-
ity. The maximum allowed stoichiometry of a DOTA con-
jugated molecule is one metallic radionuclide per molecule,
and this may limit the dose effectively delivered to the tumor.
Thispromptedus to synthesize and test newbiotin derivatives,
carrying two DOTA groups per molecule (BisDOTA set).
Substantially, BisDOTAare biotinsmodified through bifunc-
tional spacers of different lengths and chemical structures,
conjugated with two molecules of DOTA. Our aim was to
label the BisDOTA set at higher specific activity than the
mono-DOTA analogue, r-BHD. In fact, each BisDOTA can
theoretically bind up to two radionuclide ions. In this way, the
radiolabeled derivatives could deliver a higher radiation dose
to the tumor and then improve the efficiency of targeted
radionuclide therapy, provided the affinity for Av is retained
at the highest level. We report herewith the synthesis of these
newbiotin derivatives featured by spacers chosenwith the aim
tohave a suitable distance between the bulkyDOTAchelating
groups and, at the same time, between them and the biotine
head (Schemes 1, 3, and 4). While two of the new derivatives
(5a and 5b) were prepared starting from the previously
reported biotin N-hexylamino derivative, precursor of r-
BHD (Schemes 1 and 3), the other compounds 12 and 16
were obtained by conjugation of biotin with the R-NH2 of a
Lysmolecule via solid phase peptide synthesis (SPPS) strategy
(Scheme 4). The avidin binding ability of BisDOTA deriva-
tives was experimentally investigated by competitive binding
studies with HABA/avidin complex, testing the thermal sta-
bility of Av/BisDOTA complexes by using CD spectroscopy.
The Lys containing BisDOTA/avidin complexes showed an
excellent stability when compared to the native (þ)-biotin.
Scheme 1. Synthesis of BisDOTA-C3
Chart 1. Carboxylate Function R to the Biotinamide
Chart 2. Structure of r-BHD
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Moreover, biotinidase stability assay was also performed on
these compounds, giving for all BisDOTA the expected good
results.
Results and Discussion
Synthesis. BisDOTA derivative 5a was prepared starting
from theN-hexylaminobiotinyl amine 1 (Scheme 1) that was
insensitive to the action of biotinidases.19 The spacer 2a was
then introduced on the amino side arm for appending the two
DOTA moieties. Notably, the spacer lengths were chosen in
order to avoid the two chelating groups hanging too far away
from the avidin pocket. The first spacer, 2a, is commercially
available as hydrogen sulfate salt. All the reaction steps were
carried out in solution. Because of the low solubility of 1 in
the commonly used organic solvents, the coupling with 2a
was carried out in NMP. The carboxy group of the spacer 2a
was activated by the uronium (aminium) salt before the
addition of the amino component.20 Moreover, the coupling
requires basic conditions, and the use of the tertiary base
NMM avoids reaction with the 2a active ester. However,
only 1 mol equiv of NMM was used for leaving most of the
secondary NH protected as the hydrochloric acid salt. In the
Fmoc deprotection of compound 3a, piperidine should be
accurately washed away because in the next step this base can
compete in the coupling with the activated DOTA. This
latter was activated following the method reported for the
synthesis of r-BHD.19 In order to minimize the risk of
reaction on the secondary amine group, the coupling was
performed at pH 7.8, and the presence of the free NH group
in the final product 5a was detected by NMR spectrum and
confirmed by the Feigl spot test.19 The synthesis of the
BisDOTA homologue, 5b, required the preparation of the
new C6-chain spacer, 2b, that was obtained starting from the
bis-(6-aminohexyl)amine 6 and following the method re-
ported by Bambino et al. for the preparation of 2b,21 by
means of an appropriate protection/deprotection sequence
(Scheme 2). In the ESI spectrum of 2b, the peak correspond-
ing to m/z 1435.1 is a Fmoc-mediated cluster due to the
experimental ionization and disappears in the MS-MS
spectrum carried out with soft ionization conditions for
avoiding fragmentation of the molecular peak. Ongoing
from this step, the reaction pathway for the preparation of
BisDOTA-C6 followed the same procedure as for BisDOTA-
C3 (5a), affording the expected compound 5b in higher yields
than the corresponding C3-derivative (Scheme 3). In com-
pounds 5a,b, the DOTA chelating groups are bonded to the
biotinylated moiety by means of one of the four acetic acid
side chains. We demonstrated in our preceding paper19 that
Scheme 2. Synthesis of the Fmoc-Protected Spacer C6 (2b)
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the use of one of theDOTAcarboxy groups for the link to the
biotinylated moiety did not significantly affected the ability
of the azamacrocycle units to chelate the radioactive ions we
used in the labeling. As depicted in Schemes 1 and 3, the
coupling of DOTA to give compounds 5a and 5b was best
achieved in aqueous solution by activating the free tetra-
acetic acid molecule with the water-soluble EDC/sulfo-NHS
system. Taking into account the necessity of activating
mainly one of the carboxylic acid groups, the solution pH
was 5.5, as previously described.19 This procedure, although
giving low yields of the pure BisDOTA-C3 andBisDOTA-C6
(25-35%), is easy to scale up and is cheap. Another critical
point of both of these synthetic routes is the preparation of
the starting amine 1 by reduction of a suspension of the
corresponding amide in THF with BH3 3THF reagent. This
reaction required a time-expensive workup of the crude
product, and the final yield is not high.19 The finds of Hains-
worth et al. on the good affinity of biotin-lysine derivatives
carrying one DOTA group for Sav17 suggested us to bond
biotin directly with the R-amino group of lysine and test the
affinity of the so obtained BisDOTA derivatives to Av and,
at the same time, their stability toward the biotinidases
action. Concerning this latter point, we considered that the
presence of two bulky groups like the DOTA moieties, very
close each other, should be a barrier against the enzymatic
hydrolysis despite the presence of an amide group near the
biotin head. On this basis, we were prompted to prepare R-
biotinamidolysine derivatives by coupling the biotin with L-
lysine suitably protected on the ε-amino group. The intro-
duction of the bifunctional spacer and the conjugation of two
DOTA groups completed the synthetic design. Aiming to
ensure a fast approach to the final derivatives, we decided to
exploit the SPPS, which is routinely used in our laboratory,
because this technique can rapidly afford the products and
allow an easy scale-up of the synthesis. Moreover, in this
technique, at the end of each step, the byproduct can be
removed from the solid phase by simple washings.
The preparation of the biotinylated lysine derivatives
BisDOTA-Lys-C3 (12) and BisDOTA-Lys-(pAB)-C3 (16) is
outlined in Scheme 4. The orthogonally protected (Fmoc/
MTT) lysine was purchased already bonded to Wang resin.
After deprotection of the R-amino group by piperidine, only
one coupling stepwith the activated (þ)-biotinwas necessary
for the conjugation. Removal of the MTT group and reac-
tion with the Fmoc-protected spacer 2a, easy to hand in
SPPS, afforded the protected diamine 11. In another syn-
thetic route, designed to move the bulk of the radiolabeled
DOTA moiety further away from the Av pocket, we pre-
pared a longer spacer holding an aromatic, rigid, structure.
In this scheme, the on-resin biotinamidolysine was smoothly
coupled with N-protected p-aminobenzoic acid (pAB)
which, after deprotection, was, in turn, coupled with 2a
giving the bis-amine 15. The poor nucleophilicity of the
amino group of pAB complicated this coupling step and
lowered the yields. Different activating agents, especially
designed for peptide synthesis, were used in this task. In
our conditions, the HATU/NMM method gave the best
results. Because the Kaiser test for establishing the level of
coupling of the NH2 group of pAB gave unreliable results,
the progress of the reaction was controlled by a series of
microcleavages. Finally, after cleavage of the Fmoc protect-
ing groups of 11 and 15, 4-foldmolar excess of tris(tert-butyl)
Scheme 3. Synthesis of BisDOTA-C6
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ester of DOTA, well soluble in DMF and activated as
reported in Scheme 4, was added giving the required BisDO-
TA. The on-resin final compounds were cleaved with a
solution of 95% TFA, 2.5% H2O, and 2.5% TIS. Notably,
the very high TFA concentration was also able to hydrolyze
the tert-butyl ester functions at room temperature (4-5 h),
affording the expected BisDOTA 12 and 16 as the free
carboxylic acids.
Testing Av Binding Ability and Thermal Stability of Av/
BisDOTAComplexes.The avidin binding activity of BisDO-
TA derivatives was determined by HABA assay in compar-
isonwith (þ)-biotin.22 The assay utilizes the observation that
HABA shows dramatic spectral changes when it binds to
avidin. Free HABA has an absorption peak at 348 nm, while
the HABA/avidin complex has strong absorption at 500 nm.
Since the affinity between HABA and avidin is relatively
weak (Kd= 5.8 10-6 M) compared to the affinity between
(þ)-biotin and avidin (Kd = 1  10-15 M), (þ)-biotin can
easily replace HABA from the HABA/avidin complex,
resulting in a decrease of absorption at 500 nm. To estimate
the apparent avidin binding affinity of biotin and BisDOTA
derivatives, several competitive binding studies have been
performed adding (þ)-biotin and corresponding BisDOTA
derivatives to the HABA/avidin sample and measuring any
change in absorbance. As shown in Figure 1, all BisDOTA
compounds were able to inhibit the HABA/avidin complex
in a dose dependent manner.
Nevertheless, because of the differences in their spacer
arms, BisDOTA-Lys-C3 (12) and BisDOTA-Lys-(pAB)-C3
(16) molecules showed an avidin binding capacity stronger
than BisDOTA-C3 and very similar to the native (þ)-biotin.
For sake of clarity, the relevantHABAdisplacement abilities
are also compared in Table 1, comprising BisDOTA-C6 that
is not reported in Figure 1.
In strict agreement with these results, the BisDOTA-C3
interaction with avidin stabilizes the complex, upon heat
denaturation, only partially if compared to wild type avidin
alone (Figure 2). In fact, the melting curve of avidin/BisDO-
TA-C3 complex shows an inflection point at about 90 C,
which is higher than that of the avidin alone (about 80 C).
Indeed, the melting curves of avidin/BisDOTA-Lys-C3
and avidin/BisDOTA-Lys-(pAB)-C3 complexes show no
valuable inflection point in the temperature range 25-95
C, similar to avidin/(þ)-biotin complex.
Results of the Evaluation of theMaximumSA.Three biotin
derivatives, namely, 5a, 12, and 16, were radiolabeled with
90Y at high SA with high RCP. In particular, RCP above
99%was obtainedwith a SAof 2.6, 5.2, and 10.6MBq/nmol.
A further increase in SA (51.2, 212, 530 MBq/nmol) showed
a decrease in RCP but still higher than 95%. The possibility
of increasing considerably the specific activity maintaining
high RCPs may represent a great advantage in the clinical
application of the avidin-biotin system. A new targeted
locoregional therapy, based on avidin and 90Y labeled
Scheme 4. Synthetic Route for BisDOTA-Lys-C3 (12) and BisDOTA-Lys-(pAB)-C3 (16)
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r-BHD, has shown great potential in the treatment of breast
cancer reducing the duration of radiotherapy.23 In this
approach, r-BHD has been labeled at a specific activity of
2.6 MBq/nmol. Using the herein described BisDOTA deri-
vatives radiolabeled at high SA may lead to a higher uptake
by the targeted tumor area administering lower 90Y activity,
thus reducing the radiation burden to nontarget organs.
Stability Assay for Biotinidases. Biocytin is the natural
substrate of the biotinidases, a hydrolytic enzyme family
normally present in human and mouse sera, involved in the
assimilation process of (þ)-biotin (vitamin H) from diet.
Activity of biotinidases in freshly collected NMS was as-
sessed by incubating commercial biocytin with NMS, at
37 C, and verifying the presence of (þ)-biotin as product
of the reaction. As shown in Figure 3 (panels A and B,
profiles 2 and 3), after 2 h of incubation, biocytin (retention
time 12 min; [M þ H]þ = 373.5 Da) was effectively hydro-
lyzed to produce a new species, at about tR= 12.5 min, with
a molecular weight [MþH]þ=245.1 Da, corresponding to
(þ)-biotin molecular weight (profile 3). Analysis of BisDO-
TA-Lys-(pAB)-C3 (16) incubated with NMS for 2 h at 37 C
(profile 4) shows that no peak, with a retention time of about
12.5 min and corresponding to (þ)-biotin, appeared, thus
underlining the resistance of 16 to biotinidases activity. In
strict agreement with these results, the peak of BisDOTA-
Lys-(pAB)-C3 was fully recovered after the incubation step.
Similar results were obtained with BisDOTA-C3, -C6, and
BisDOTA-Lys-C3 derivatives (data not shown).
Conclusions
In summary, this study describes the syntheses and char-
acterizations of four new biotin derivatives resistant to the
biotinidases action and able to carry two radioisotopes for
ligand unit. Radiolabeling experiments with 90Y confirmed the
expected achievable high specific activity. Experimental data
on the thermal stability of avidin/ligand complexes suggested,
at least for thederivatives containing a lysine spacer, a veryhigh
affinity for the protein and pointed out the different behavior
between the spacers containing or not the lysine chain. Never-
theless, further studies in vitro and in vivo with the labeled
BisDOTA will be necessary before considering these com-
pounds good candidates for improving RIT protocols.
Experimental Procedures
General. DOTA and tris(tert-butyl)-DOTA were purchased
fromMacrocyclics (Richardson, TX) while standard (þ)-biotin
(B4639) and biocytin (B4261) were purchased from Sigma-
Aldrich. N,N-Bis[3-(Fmoc-amino)propyl]glycin hydrogen sul-
fate potassium salt (2a) was from Fluka (Sigma-Aldrich,
Switzerland). Fmoc-Lys(MTT)-Wang resin (100-200 mesh)
was from Novabiochem AG (Laufelfingen, Switzerland), 6-Cl
HOBt from Luxembourg (Israel), HATU from PerSeptive Bio-
system, and TBTU from Chem Impex International (Wood
Dale, IL). Peptide-synthesis grade DMF was from Scharlau
(Barcelona, Spain). HPLC-grade MeCN was purchased from
Carlo Erba (Italy). Dry solvents were distilled immediately
before use: THF over sodium/benzophenone. All other chemi-
cals were commercial compounds andwere used as received. 90Y
chloride in hydrochloric acid (0.04M)was purchased fromQSA
Global, Braunschweig, Germany. HABA was from Sigma-
Aldrich (Switzerland) and avidin from Tecnogen (Italy). 1H
NMR spectra were recorded on a Varian Gemini 200 MHz or
Varian Inova 400 MHz spectrometer in DMSO-d6, D2O, or
CDCl3. Chemical shifts are reported in ppm (δ) downfield from
tetramethylsilane. CD spectra were acquired on Jasco J-715
spectropolarimeter equipped with a thermostatic water bath.
Electrospray ionization mass spectra (ESI-MS) were acquired
on LCQ-Advantage ESI ion trap spectrometer (Thermo
Finnigan) for positive and negative ions detection. Fast atom
Table 1. Displacement of HABA from Avidin Complex by Biotin and
BisDOTA Derivatives (31 μM, Av/Ligand = 1:4)
compd HABA/Av inhibition, %
(þ)-biotin 100
BisDOTA-C3 66
BisDOTA-C6 64
BisDOTA-Lys-C3 95
BisDOTA-Lys-(pAB)-C3 97
Figure 1. Inhibition of the HABA/avidin complex by (þ)-biotin ([,
black line), BisDOTA-Lys-C3 (9, red line), BisDOTA-Lys-(pAB)-C3
(b, green line), and BisDOTA-C3 (2, blue line). Data are representative
of three different experiments.
Figure 2. Melting curves of avidin (brown line), avidin/BisDOTA-
C3 complex (blue line), avidin/BisDOTA-Lys-C3 complex (red line),
Avidin/BisDOTA-Lys-(pAB)-C3 complex (green line), and avidin/
(þ)-biotin complex (black line).
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bombardment mass spectrum (FAB-MS) was registered on a
Finnigan-MAT TSQ70 triple stage quadrupole apparatus
equipped with an Ion Tech (Teddington, U.K.) atom gun with
xenon as bombarding gas and on a VG 70-250 FAB-MS
spectrometer (Micromass). The purity of the final compounds
(>95%) was checked by HPLC and, in some cases, also by
combustion analysis, performed on a Perkin-Elmer 240 C
elemental analyzer.
Chromatography. TLC was carried out on SiO2 (Merck, 60 A˚
F254), and spots were located with UV light (254 and 366 nm),
methanolic ninhydrin, Fluram (Fluka; fluorescamine, 4-phenyl-
spyro[furan-2(3H),10-isobenzofuran]-3,30-dione) in acetone,
Cl2/O-tolidine [O-tolidine (75 mg)], AcOH (3 mL), and KI (21
mg) in water (47 mL). SPE was performed on RP-LiChroprep
resins, and FCC purifications were performed on silica gel 60,
40-63 μm, as detailed in the text. Semipreparative HPLC was
carried out by a Supelco C18 180 A˚ (250 mm  10 mm, 5 μm,
metals<10ppm) columat 28 Cusing aBeckmanGoldNoveau
instrument (detector diode array). Analytical HPLCwas run on
5 μm Phenomenex Jupiter columns C18 300 A˚ (250 mm  4.6
mm). The solvent systems used for gradients were A (0.1%TFA
in H2O) and B (0.1% TFA in CH3CN). The flow rates were
1 mL/min for analytical HPLC and 4 mL/min for semiprepara-
tive HPLC, with the linear gradients indicated when necessary.
LC-ESI MS analyses were performed by a Phenomenex Aqua
C18 column (5 μm, 150 mm  2.0 mm) (flow rate, 200 μL/min)
or a Vydac 218MS51 C18 mass spectometry column (5 μm,
250 mm  1.0 mm) (flow rate, 300 μL/min) on a Thermo
Finnigan Surveyor HPLC system coupled to the ESI-MS, using
the solvent systems H2O (A), MeCN (B), 1% TFA in H2O (C).
Silica gel ITLCpaper strips for the labeling procedurewere from
ITLC-SG, Gelman Science, Ann Arbor, MI. The radiochroma-
tographic profile was determined by Cyclone (Packard
BioScience, Meriden, CT). For determination of the serum
stability, the apparatus was a C2-C18 RP-HPLC column (2.1
mm  100 mm, GE Healthcare) connected to a LC-ESI-MS
system (LCQ Duo, Thermo-Finnigan). The solvent systems
used were A (0.08% TFA in H2O) and B (0.08% TFA in
CH3CN).
Synthesis of BisDOTA-C3 (5a). Bis[(9H-fluoren-9-yl)methyl]-
3,30-[2-oxo-2-[[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno-
[3,4-d]imidazol-4yl]pentyl]amino]hexyl]amino]ethylazanodiyl] Bis-
(propane-1,3-diyl) Dicarbamate (3a). The compound was
obtained by adding the activated (þ)-biotin (2 mol equiv) in
two steps to a solution of 2a in NMP and stirring for 5 h at room
temperature. The product was purified by SPE (LiChroprep
RP8, 40-63μm; 170mm 20mm; eluent, CH3CN/H2O/HCl=
50:50:0.1, 1 mL/min), and the yellow-orange oil was checked by
TLC inspection (CH3CN/H2O/HCl = 50:50:0.1). Analytical
HPLC (30-100%of B in 20min): tR=15.4min. 1HNMR (298
K), δ (DMSO-d6, 200MHz): 9.63 (br s, 1H), 8.64 (br s, 3H), 7.87
(d, 4H), 7.65 (d, 4H), 7.43-7.27 (m, 8H), 6.41 (d, 2H), 4.31-4.14
(m, 8H), 3.85 (s, 2H), 3.14-3.03 (m, 11H), 2.82-2.76 (m, 4H),
2.6 (d, 2H), 1.76-1.25 (m, 20H). ESI-MS (positive ions): m/z
calcd [M þ H]þ 944.5; found 944.5 [M þ H]þ.
2-[Bis(3-aminopropyl)amino]-N-[6-[[5-[(3aS,4S,6aR)-hexahy-
dro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]pentyl]amino]hexyl]-
acetamide (4a). The compound was obtained after evaporation
of DMF solution, dissolved inMeOH, and precipitated by ethyl
ether. The solid, dissolved in H2O and lyophilized, was then
purified by SPE (LiChroprep RP18, 25-40 μm, 170 mm  20
mm; eluent, H2O/100%-MeOH 4-100%). The pure com-
pound was collected from the aqueous fractions as a colorless
solid. Analytical HPLC (5-15% of B in 30 min): tR=18.2 min.
1H NMR (298 K), δ (CDCl3, 200 MHz): 8.12 (br s, 2H), 6.45
(s, 2H), 4.35-4.25 (m, 1H), 4.15-4.05 (m, 1H), 3.59-2.95 (m,
7H), 2.95-2.70 (m, 12H), 2.50 (d, 2H), 1.80-1.20 (m, 20 H).
ESI-MS (positive ions): m/z calcd [M þH]þ 499.4; found 500.4
[M þ H]þ.
2,20,20 0-[10-[2,9-Dioxo-22-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-
thieno[3,4-d]imidazol-4-yl]-7-[3-[2-[4,7,10-tris(carboxymethyl)-1,4,
7,10-tetraazacyclododecane-N-1-yl]acetamide]propyl]-3,7,10,17-
tetraazadocosyl]-1,4,7,10-tetraazacyclododecane-N0,N0 0,N00 0-1,4,
7-triyl]triacetic Acid (5a). After the coupling of 4a with DOTA,
the aqueous solution was evaporated to dryness and the crude
compoundwas purified by SPE as for 4a. Crude 5awas collected
from the methanolic solution and further purified by semipre-
parative RP-HPLC, affording the pure compound as a colorless
Figure 3. LC-MS analyses of BisDOTA derivatives resistance to biotinidase activity: (A) UV chromatograms from C2-C18 RP-HPLC
column; (B) total ionic current (TIC) from ESI source; (1) NMS; (2) biocytin in NMS at t= 0 min.; (3) biocytin in NMS incubated for 2 h at
37 C; (4) BisDOTA-Lys-(pAB)-C3 in NMS incubated for 2 h at 37 C. In panel A arrows indicate the identified species, with their theoretical
molecular weight as protonated species reported in parentheses and expressed in daltons. In panel B arrows indicate the corresponding
molecular weights experimentally assigned and expressed in daltons.
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solid. 1HNMR (298K), δ (D2O, 400MHz): 4.51-4.48 (m, 1H),
4.32-4.29 (m, 1H), 3.92 (br s, 2H), 3.72-2.65 (m, 65H),
1.81-1.23 (m, 20H). ESI-MS (positive ions): m/z calcd [M þ
H]þ 1272.73, [M þ 2H]2þ 636.86 (100%); found 1272.71 [M þ
H]þ, 637.2 [M þ 2H]2þ. Anal. (C56H101N15O16S 3 6TFA 3 5H2O)
C, H, N.
Synthesis of the C6-Chain Spacer (2b). 2,2
0-(Iminodi-6,1-hexa-
nediyl)bis-1H-isoindole-1,3(2H)-dione (7). The compound was
collected as an orange oil and used in the next step without
further purification. 1H NMR (298 K), δ (CDCl3, 200 MHz):
7.81-7.77 (m, 4H), 7.68-7.64 (m, 4H), 3.62 (t, 4H), 2.57 (t, 4H),
2.20 (s, 1H), 1.75-1.55 (m, 4H), 1.5-1.4 (m, 8H), 1.35-1.2 (m,
4H). ESI-MS (positive ions): m/z calcd [M þ H]þ 476.3; found
476.5 [M þ H]þ.
N,N-Bis[6-(1,3-dihydro-1,3-dioxo-2H-isoindole-2-yl)hexyl]-
glycine Ethyl Ester (8). The compound was collected from
evaporation of DMF and purified through FCC (eluent,
AcOEt/petroleum ether= 1:1), affording 8 as an yellow-orange
oil. Analytical HPLC (30-80% of B in 20 min), tR= 15.6 min.
1H NMR (298 K), δ (CDCl3, 200 MHz): 7.81-7.75 (m, 4H),
7.70-7.64 (m, 4H), 4.10 (q, 2H), 3.62 (t, 4H), 3.24 (s, 2H), 2.49 (t,
4H), 1.66-1.56 (m, 4H), 1.44-1.26 (m, 15H). ESI-MS (positive
ions): m/z calcd [M þ H]þ 562.3; found 562.4 [M þ H]þ.
N,N-Bis(6-aminohexyl)glycine (9). Analytical HPLC (20-
60% of B in 20 min): tR = 6.47 min.
1H NMR (298 K), δ
(DMSO-d6, 200 MHz): 10.22 (br s, 1H), 8.18 (br s, 4H), 4.06 (s,
2H), 3.13-3.08 (m, 4H), 2.8-2.55 (m, 4H), 1.58-1.55 (m, 8H),
1.4-1.15 (m, 8H). ESI-MS (positive ions): m/z calcd [M þ H]þ
274.3; found 274.3 [M þ H]þ.
N,N-Bis[[[6-(9H-fluoren-9-ylmethoxy)carbonyl]amino]hexyl]-
glycine (2b). The compound was extracted from the reaction
solution previously acidified with 3 M HCl. The crude product
was purified by FCC (eluent, CHCl3/MeOH = 3:1) to provide
compound 2b. Analytical HPLC (30-100% of B in 20 min): tR
= 19.67 min. 1H NMR (298 K), δ (CDCl3, 400 MHz): 7.71 (d,
4H), 7.56 (d, 4H), 7.38-7.22 (m, 8H), 4.33-4.29 (m, 2H), 4.16
(d, 4H), 3.60-3.44 (m, 2H) 3.3-2.95 (m, 8H), 1.72-1.20 (m,
16H). ESI-MS (positive ions):m/z calcd [MþH]þ 718.4, [2Mþ
H]þ 1434.8; found 718.4 [M þ H]þ, 1435.1 [2M þ H]þ.
Synthesis of BisDOTA-C6 (5b). N,N-Bis[(9H-fluoren-9-
yl)methyl]3,30-[2-oxo-2-[[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-
1H-thieno[3,4-d]imidazol-4-yl]pentyl]amino]hexyl]amino]ethyl-
azanodiyl]bis(hexan-1,6-diyl)dicarbamate (3b). After evapora-
tion of NMP under reduced pressure, the oily residue was
treated with H2O and then purified by SPE (LiChroprep RP8,
40-63μm, 170mm 20mm; eluent,H2O/CH3CN=2:3, 1mL/
min), affording compound 3b. Analytical HPLC as for 2b: tR=
16.57 min. 1H NMR (298 K), δ (DMSO-d6, 200 MHz):
7.84-7.20; Fmoc. ESI-MS (positive ions): m/z calcd [M þ H]þ
1028.6; found 1028.5 [M þ H]þ.
2-[Bis(6-aminohexyl)amino]-N-[6-[[5-[(3aS,4S,6aR)-hexahydro-
2-oxo-1H-thieno[3,4-d]imidazol-4-yl]pentyl]amino]hexyl]aceta-
mide (4b). The crude compound was collected and purified as
reported for 4a. However, from the SPE eluate the pure product
was found in the methanolic fraction as a colorless solid. Analy-
tical HPLC (5-30%of B in 30min): tR=18.48min. 1HNMR δ
(DMSO-d6, 200 MHz): Fmoc signals disappeared. ESI-MS
(positive ions):m/z calcd [MþH]þ 584.5; found 584.7 [MþH]þ.
2,20,200-[10-[16-Carboxy-2,9-dioxo-22-[(3aS,4S,6aR)-hexahy-
dro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-7-[6-[2-[4,7,10-tris(carbo-
xymethyl)-1,4,7,10-tetraazacyclododecane-N-1-yl]acetamide]-
hexyl]-3,7,10,17-tetraazadocosyl]-1,4,7,10-tetraazacyclodo-
decane-N0,N0 0,N0 0 0-1,4,7-triyl]triacetic Acid (5b). The workup
was carried out as reported for compound 5a. Analytical HPLC
as for 4b: tR =19.8 min.
1H NMR (298 K), δ (D2O, 400 MHz):
4.55-4.50 (m, 1H), 4.33-4.30 (m, 1H), 3.98 (br s, 2H),
3.89-2.64 (m, 65H), 1.94-1.14 (m, 32H). ESI-MS (positive
ions): m/z calcd [M þ H]þ 1356.82, [M þ 2H]2þ 678.91; found
1356.7 [M þ H]þ, 679.2 [M þ 2H]2þ (100%). Anal.
(C62H113N15O16S 3 9HCl 3 8H2O) C, H, N.
Synthesis of BisDOTA-Lys-C3 (12) and BisDOTA-
Lys-(pAB)-C3 (16). The products were synthesized using the
classical SPPS method, on Fmoc-Lys(MTT)-Wang resin using
the manual synthesizer PLS 4  4. Each coupling step was
checked by performing a Kaiser test on microcleavages.24
Briefly, the biotin was coupled to the deprotected lysine accord-
ing to the TBTU/HOBt/NMM activation method, using a 2-
fold molar excess of activated biotin. The removal of MTT
group was performed with a solution of 1% TFA in DCM,
containing 5% TIS as scavenger. The spacers 2a and 13 were
introduced by adding 2-fold molecular excess of the activated
reagents, while the DOTA amount was 4 mol equiv. The
intermediate compounds were checked by microcleavages and
HPLC-MS spectra of the isolated compounds. After the
DOTA coupling, the cleavage solution was concentrated under
nitrogen fluxing, Et2O was added, and the suspension was
centrifuged and lyophilized. The crude products were purified
by RP-HPLC (5-30% of B in 30 min). The yields were
calculated on the basis of the resin loading.
2,20,20 0-[10-[16-Carboxy-2,9-dioxo-22-[(3aS,4S,6aR)-hexahy-
dro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-7-[3-[2-[4,7,10-tris-
(carboxymethyl)-1,4,7,10-tetraazacyclododecan-N-1-yl]aceta-
mido]propyl]-3,7,10,17-tetraazadocosyl]-1,4,7,10-tetraazacyclo-
dodecane-N0,N0 0,N00 0-1,4,7-triyl]triacetic Acid (12). Analytical
HPLC was performed as for 5b: tR = 11.1 min.
1H NMR (298
K), δ (D2O, 400 MHz): 4.51-4.48 (m, 1H), 4.32-4.29 (m, 1H)
4.23-4.19 (m, 1H), 3,93-2.68 (m, 63H), 2.21 (t, 2H), 1.84-1.29
(m, 16H). ESI-MS (positive ions): m/z calcd [M þH]þ 1316.68,
[M þ 2H]2þ 658.84; found 1316.5 [M þH]þ, 659.2 [M þ 2H]2þ
(100%). Anal. (C56H97N15O19S 3 6H2O 3 6TFA) C, H, N.
2,20,200-[10-[2-[3-[[3-[2-[4,7,10-Tris(carboxymethyl)-1,4,7,10-
tetraazacyclododecan-N-1-yl]acetamido]propyl][2-[4-[5-carboxy-
5-[5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido]-
pentylcarbamoyl]phenylamino]-2-oxoethyl]amino]propylamino]-
2-oxoethhyl]-1,4,7,10-tetraazacyclododecane-N0,N0 0,N00 0-1,4,
7-triyl]triacetic Acid (16). Analytical HPLC conditions were as
for 12: tR = 12.97 min.
1H NMR (298 K), δ (D2O, 400 MHz):
7.70-7.52 (dd, 4H), 4.44-4.41 (m, 1H), 4.26-4.23 (m, 1H),
4.20-4.18 (m, 1H), 3.70-3.06 (m, 60H), 2.83-2,80 (m, 2H),
2.62-2.58 (m, 1H), 2.15-2.10 (m, 2H), 1.91-1.12 (m, 16H). ESI
MS (positive ions): m/z calcd [M þ H]þ 1435.72, [M þ 2H]2þ
718.86; found 1436.6 [M þ H]þ, 718.9 [M þ 2H]2þ (100%).
Anal. (C63H102N16O20S 3 7H2O 3 8TFA) C, H, N.
HABA Assay. Preliminary experiments were performed by
varying the concentration ofHABA (from 3mM to 0.3 μM) and
avidin (15.1, 7.6, and 3.8 μM) to calculate their optimal con-
centrations in the competitive binding studies. In the final
experiments, carried out in 1 mL sample cuvettes, various
concentrations of competitors [(þ)-biotin and BisDOTA de-
rivatives] were added to the HABA/Av complex, obtained by
mixing avidin and HABA to a final concentration of 7.6 and
0.25 μM, respectively. Changes in absorbance were measured at
500 nm. All experiments were in triplicate, and the% inhibition
was calculated as {[(absorbance with competitor) - (absor-
bance without HABA)/(Av complex)]/[(absorbance without
competitor) - (absorbance without HABA)/(Av complex)]} 
100.
CD Assay on Avidin/Bis-DOTA Complexes Stability. Each
spectrum (195-260 nm) was obtained from averaging three
scans and subtracting the contribution from the buffer solution.
Other experimental settings were as follows: 20 nm  min scan
speed, 2.0 nmbandwidth, 0.2 nm resolution, 50mdeg sensitivity,
and 4 s response. Melting curves of wild type avidin, with or
without 4 equiv of D-biotin and its BisDOTA derivatives, were
recorded by following the decrease of dichroic signal at 225 nm,
keeping the temperature in the range 25-95 C. Instrument
settings were as follows: bandwidth 1 nm, response 0.5 s, data
pitch 1 C, temperature slope 10 C/min. At every temperature
increment of 5 C, a far-UV CD spectrum was collected in the
experimental conditions reported above.
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General Radiolabeling Procedure.Radiolabeling general pro-
cedure was performed using the three derivatives BisDOTA-C3
(5a), BisDOTA-Lys-C3 (12), and BisDOTA-Lys-(pAB)-C3 (16)
at a concentration of 3mg/mL in saline. Equal volumes of 1.0M
sodium acetate buffer (pH 5.0) and of the radionuclide chloride
solution were used. In each experiment, biotin solution was
added to the buffer and transferred into the radionuclide
supplier vial. The mixture was then mixed and heated at 95 C
for 30 min. RCP was assayed in triplicate for each radiolabeled
sample by ITLC. An aliquot (usually 0.05 mL) of the radiola-
beling solution was mixed with 0.2 mL of an avidin-DTPA
solution (0.4 mMAv and 2.5mMDTPA, final pH 6.0) and kept
at room temperature for 5 min. Subsequently, an amount of 5
μL of the radioactive mixture was spotted on a silica gel ITLC
paper strip and then developed in saline solution. In this
chromatographic system, Av-radio-biotin complex remains at
the origin whereas free radiometal, bound toDTPA,migrates to
the solvent front. The radiochromatographic profile was deter-
mined by an autoradiographic system using high performance
storage phosphor screen and RCP consequently calculated.
Labeling yields greater than 97% were routinely achieved.
High Specific Activity (SA) Radiolabeling. To determine the
achievable SA (expressed as MBq/nmol), the three derivatives
5a, 12, and 16 were radiolabeled with 90Y at the following
increasing of SA: 2.6, 5.2, 10.6, 51.2, 212, 530 MBq/nmol.
RCP was determined in each sample as previously described.
Serum Stability. Normal mouse serum, freshly collected just
before each experiment, was used as the source of biotinidase
activity. Each experiment was carried out by mixing 50 μL of
NMS with 10-25 μL of samples (BisDOTA derivatives or
Biocytin). The volume was adjusted to 500 μL with reaction
buffer (100 mM sodium acetate, pH 5.5), and each sample was
incubated at 37 Cinwater bathup to2h.To stop the reaction, an
amount of 50 μL of each sample was diluted 10-fold with 0.08%
TFA (v/v) in water, either before and after incubation, and 40 μL
of this solution was applied to the HPLC columns. The chroma-
tographic separations were carried out at a flow rate of 0.2 mL/
min and by applying a gradient from 2% to 60% of B in 20 min.
Main settings of ESI source were the following: spray voltage,
4.2 kV; capillary temperature, 300 C; capillary voltage, 6 V.
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